RAPS Publishes Regulatory Intelligence 101 Book
Regulatory Intelligence 101 serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory intelligence (RI), the act of monitoring and analyzing available regulatory information, has become a crucial skill for regulatory professionals working in the pharmaceutical, medical device and biotechnology sectors. Regulatory Intelligence 101, new from the Regulatory Affairs Professionals Society (RAPS) serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory Intelligence 101 examines available regulatory intelligence tools, both free and those requiring a subscription, and gives tips on how to gatherinformation. Chapters cover everything from the basic regulatory intelligence toolbox to setting up a regulatory intelligence department within a company.
“This book is the culmination of my 14-year love affair with RI, a field that has allowed my affinity for regulatory and love of the profession to shine through,” writes author Meredith Brown-Tuttle, RAC, in the book’s introduction. “It reflects the contributions to the growth and development of RI through the years, and I am proud to have been part of the process.”
According to RAPS’ 2014 Scope of Practice & Compensation Report for the Regulatory Profession, regulatory intelligence currently represents an average of about 6% of regulatory professionals’ job responsibilities.
Regulatory Intelligence 101 is available from the RAPS Store for $44.95 (US) for RAPS members or $54.95 for nonmembers.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
